Brief: Intelgenx Receives FDA GDUFA Date For Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
25/10/2022 15:26
Oct 25 (Reuters) - Intelgenx Technologies Corp IGX.TO :
* INTELGENX RECEIVES FDA GDUFA DATE FOR XIROMED-PARTNERED
DEVELOPMENT CANDIDATE, BUPRENORPHINE BUCCAL FILM
* INTELGENX RECEIVES FDA GDUFA DATE FOR XIROMED-PARTNERED
DEVELOPMENT CANDIDATE, BUPRENORPHINE BUCCAL FILM
* INTELGENX TECHNOLOGIES CORP - GENERIC DRUG USER FEE ACT
DATE OF
APRIL 28, 2023
Source text for Eikon: ID:nGNX9h1614
Further company coverage: IGX.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA